Brookstone Capital Management Purchases 5,735 Shares of iShares Biotechnology ETF $IBB

Brookstone Capital Management boosted its position in iShares Biotechnology ETF (NASDAQ:IBB) by 91.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,035 shares of the financial services provider’s stock after acquiring an additional 5,735 shares during the period. Brookstone Capital Management’s holdings in iShares Biotechnology ETF were worth $2,031,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in IBB. BNP Paribas Financial Markets increased its holdings in shares of iShares Biotechnology ETF by 313.2% during the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock valued at $276,526,000 after acquiring an additional 1,451,820 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of iShares Biotechnology ETF during the third quarter worth approximately $65,083,000. JPMorgan Chase & Co. lifted its holdings in shares of iShares Biotechnology ETF by 27.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock worth $153,039,000 after purchasing an additional 226,852 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of iShares Biotechnology ETF by 140.8% in the 1st quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock worth $5,330,000 after purchasing an additional 143,893 shares in the last quarter. Finally, Caption Management LLC acquired a new stake in iShares Biotechnology ETF in the 3rd quarter valued at $11,333,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of IBB stock opened at $169.43 on Friday. The firm has a fifty day simple moving average of $170.70 and a two-hundred day simple moving average of $164.77. iShares Biotechnology ETF has a 12 month low of $107.43 and a 12 month high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 20th. Stockholders of record on Tuesday, March 17th were issued a dividend of $0.1218 per share. This represents a $0.49 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Tuesday, March 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.